Abstract：
:The advent of social media has led to the ability for individuals all over the world to communicate with each other, in real time, about mutual topics of interest in an unprecedented manner. Recently, the use of social media has increased among people interested in healthcare and medical research, particularly in the field of hematology and oncology, a field which frequently experiences rapid shifts of information and novel, practice-changing discoveries. Among the many social media platforms available to cancer patients and providers, one platform in particular, Twitter, has become the focus for the creation of disease-specific communities, especially for those interested in, affected by, or those who perform research in the fields of rare cancers, which historically have had a dearth of reliable information available. This article will focus on the initiation and progress of one such Twitter hematology/oncology community, #mpnsm, which was originally created for the purpose of serving as a venue for improving the interaction among patients, providers, researchers, and organizations with interest in the myeloproliferative neoplasms (MPNs) and to further the availability of reliable up-to-date analysis; relevant expert commentary; and readily usable information for patients, providers, and other groups interested in this field.
journal_name
Curr Hematol Malig Repjournal_title
Current hematologic malignancy reportsauthors
Pemmaraju N,Gupta V,Mesa R,Thompson MAdoi
10.1007/s11899-015-0287-9subject
Has Abstractpub_date
2015-12-01 00:00:00pages
413-20issue
4eissn
1558-8211issn
1558-822Xpii
10.1007/s11899-015-0287-9journal_volume
10pub_type
杂志文章,评审abstract：:Myelodysplastic syndromes (MDS), or myelodysplasia, are a heterogeneous group of bone marrow disorders characterized by progressive cytopenias and a propensity to evolve into acute leukemia. The only curative strategy in the treatment of MDS is stem cell transplantation. The advent of hypomethylating agents and, more ...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章
doi：10.1007/s11899-008-0002-1
更新日期：2008-01-01 00:00:00
abstract：:Among the few drugs that have shown a benefit for patients with acute myeloid leukemia (AML) in randomized clinical trials over the last several decades is the CD33 antibody-drug conjugate, gemtuzumab ozogamicin (GO). Undoubtedly, this experience has highlighted the value of antigen-specific immunotherapy in AML. A wi...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-015-0250-9
更新日期：2015-06-01 00:00:00
abstract：PURPOSE OF REVIEW:To provide an update on the pathogenesis of enteropathy-associated T cell lymphoma (EATL) and its relationship with refractory celiac disease (RCD), in light of current knowledge of immune, genetic, and environmental factors that promote neoplastic transformation of intraepithelial lymphocytes (IELs)....
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-018-0459-5
更新日期：2018-08-01 00:00:00
abstract：PURPOSE OF REVIEW:CMV DNA polymerase inhibitors such as ganciclovir and foscarnet have dramatically reduced the burden of CMV infection in the HCT recipient. However, their use is often limited by toxicities and resistance. Agents with novel mechanisms and favorable toxicity profiles are critically needed. We review re...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-020-00557-6
更新日期：2020-04-01 00:00:00
abstract：:Mycosis fungoides (MF) and its leukemic variant, Sézary syndrome (SS), are malignancies of skin-homing T cells that comprise the majority of cutaneous T cell lymphomas (CTCL). Treatment of CTCL is limited and can be approached by skin-directed therapy or systemic therapy. Recent investigations into the pathogenesis of...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-015-0293-y
更新日期：2015-12-01 00:00:00
abstract：:Patients with hematologic malignancies are increasing being prescribed oral anticancer medications (OAMs) and/or biologics. These newer targeted OAMs are associated with a host of practical and pharmacoeconomic implications for patients and healthcare providers. Issues such as safety, procurement challenges, and the n...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-016-0325-2
更新日期：2016-08-01 00:00:00
abstract：:No therapy is uniformly effective in the management of immunoglobulin light chain amyloidosis (AL amyloidosis). Despite the common generalization, therapy is highly effective. Options available to patients with AL amyloidosis include high-dose therapy, but this is applicable to only about one fourth of patients. Thera...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-009-0013-6
更新日期：2009-04-01 00:00:00
abstract：PURPOSE OF REVIEW:Novel immunotherapies such as checkpoint inhibitors, bispecific antibodies, and chimeric antigen receptor T cells are leading to promising responses when treating solid tumors and hematological malignancies. T cell neoplasms include leukemia and lymphomas that are derived from T cells and overall are ...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-018-0480-8
更新日期：2018-12-01 00:00:00
abstract：PURPOSE OF REVIEW:The use of circulating tumor DNA (ctDNA) for the purposes of diagnosis, prognosis, assessment of treatment response, and monitoring for relapse is a new and developing field in lymphoma. This review aims to summarize many of the most recent advances in ctDNA applications. RECENT FINDINGS:Recent studi...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-018-0468-4
更新日期：2018-10-01 00:00:00
abstract：:Primary mediastinal B-cell lymphoma (PMBCL) is a relatively rare lymphoma subtype affecting mainly young adults. Its molecular signature and clinical features resemble classical Hodgkin lymphoma. The optimal chemotherapy for this lymphoma subtype has not been established. The addition of rituximab to anthracycline bas...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章
doi：10.1007/s11899-014-0219-0
更新日期：2014-09-01 00:00:00
abstract：:In patients with acute leukemia, measurements of minimal residual disease (MRD) provide unique information on response to treatment. The most useful currently available MRD assays are polymerase chain reaction amplification of fusion transcripts and rearranged antigen-receptor genes and flow cytometric detection of ab...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章
doi：10.1007/s11899-008-0022-x
更新日期：2008-07-01 00:00:00
abstract：:A high risk of arterial and venous thrombosis is the hallmark of chronic myeloproliferative neoplasms (MPNs), particularly polycythemia vera (PV) and essential thrombocythemia (ET). Clinical aspects, pathogenesis and management of thrombosis in MPN resemble those of other paradigmatic vascular diseases. The occurrence...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-013-0176-z
更新日期：2013-12-01 00:00:00
abstract：:Advances in chemotherapy administration have made acute lymphoblastic leukemia (ALL) a curable disease; however, most patients will relapse, despite readily attaining a complete remission. Treatment of relapse has shown dismal results with little advances made in the recent decades. Antigenic-directed therapy of ALL c...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-012-0120-7
更新日期：2012-06-01 00:00:00
abstract：:Acute myeloid leukemia (AML) is a complex clonal disorder. The disease is characterized by chromosomal and molecular abnormalities that propagate and expand the abnormal clone(s). The main goal of therapy is to achieve and ultimately maintain a complete remission. In the younger AML patient (less than 60 years of age)...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-016-0339-9
更新日期：2016-10-01 00:00:00
abstract：:The introduction of imatinib represented a breakthrough in the treatment of chronic myelogenous leukemia (CML). However, about 20% of patients treated in early chronic-phase CML are off therapy after 6 years because of resistance or intolerance, and most patients taking imatinib remain BCR-ABL-positive at the molecula...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章
doi：10.1007/s11899-008-0012-z
更新日期：2008-04-01 00:00:00
abstract：:Allogeneic haematopoietic cell transplantation continues to be an important curative therapy for acute lymphoblastic leukaemia (ALL). Traditionally accepted indications for allografting adult ALL patients need reevaluation in light of outcomes with paediatric-like intensive regimens. Minimal residual disease status an...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-017-0371-4
更新日期：2017-04-01 00:00:00
abstract：:Advances in drug discovery have led to the use of effective targeted agents in the treatment of hematologic malignancies. Drugs such as proteasome inhibitors in multiple myeloma and tyrosine kinase inhibitors in chronic myeloid leukemia and non-Hodgkin lymphoma have changed the face of treatment of hematologic maligna...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-017-0369-y
更新日期：2017-06-01 00:00:00
abstract：:Chronic myelomonocytic leukemia is a clonal malignancy of the ageing hematopoietic stem cell characterized by a biased differentiation leading to persistent monocytosis and inconstant hypersensitivity of myeloid progenitors to granulo-monocyte colony-stimulating factor (GM-CSF). Cytogenetic abnormalities identified in...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-014-0225-2
更新日期：2014-12-01 00:00:00
abstract：:Compared with acute lymphoblastic leukemia (ALL) in older children, ALL in infants has a dismal outcome because rearrangements of the mixed-lineage leukemia (MLL) gene occur in about 80% of these patients, leading to an aggressive type of leukemia. With most recent therapies, about 50% long-term event-free survival is...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-009-0023-4
更新日期：2009-07-01 00:00:00
abstract：PURPOSE OF REVIEW:Determine if therapy of chronic myeloid leukaemia (CML) is a model for treating other cancers. RECENT FINDINGS:CML has a relatively homogeneous phenotype and genotype and is caused by one mutation, BCRABL1, in every instance. In contrast, most other leukaemias, haematologic cancers and solid cancer h...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-019-00555-3
更新日期：2019-12-01 00:00:00
abstract：:Follicular lymphoma (FL), the most common indolent lymphoma, typically presents in advanced-stage disease. Currently available therapy does not generally result in a curative outcome, but survival in FL has improved since the introduction of anti-CD20 monoclonal antibody immunotherapy. The goals of treatment include p...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-011-0099-5
更新日期：2011-12-01 00:00:00
abstract：:Chronic myeloid leukemia (CML) arises as a consequence of a chromosomal translocation giving rise to the Philadelphia chromosome and Bcr-Abl oncogene. CML is a clonal disease of stem cell origin and an excellent example of a malignancy in which tumor-initiating cells may hold the key to disease eradication. The known ...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-010-0043-0
更新日期：2010-04-01 00:00:00
abstract：:The prognosis value of interim positron emission tomography (PET) remains controversial in diffuse large B-cell lymphoma (DLBCL) patients because of the absence of consensus on criteria able to early identify good and bad responders to treatment. Visual interpretation using the International Harmonization Project (IHP...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-012-0129-y
更新日期：2012-09-01 00:00:00
abstract：PURPOSE OF REVIEW:Antibody-drug conjugates are a new class of therapeutic agents in the treatment of B cell malignancies. In this review, we summarize the recent developments of polatuzumab vedotin in the treatment of relapsed or refractory diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL). RECENT FIN...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-020-00572-7
更新日期：2020-04-01 00:00:00
abstract：:Hodgkin's lymphoma (HL) is a relatively rare disease accounting for 15 % of all lymphoma. This disease has developed from an incurable disease to the adult malignancy with the most favorable prognosis. With current therapeutic approaches consisting of polychemo- and small-field radiotherapy, up to 80 % of all patients...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-015-0262-5
更新日期：2015-09-01 00:00:00
abstract：:The peripheral T cell lymphomas (PTCLs) are a heterogeneous group of neoplasms for which standardized treatment approaches remain elusive. A number of new therapeutic agents have become available, of which monoclonal antibodies (MAbs) represent a powerful tool for targeted treatment of PTCLs. Therapeutic MAbs vary in ...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-015-0290-1
更新日期：2015-12-01 00:00:00
abstract：:Most non-Hodgkin lymphomas (NHL) are of B-cell origin; only about 10% are T-cell or NK-cell lymphomas. The clinical features of T/NK-cell lymphomas differ from those of B-cell lymphomas: advanced stage and extranodal disease are more common and the prognosis is worse. Several studies have confirmed that 2-[fluorine-18...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章
doi：10.1007/s11899-011-0098-6
更新日期：2011-12-01 00:00:00
abstract：:Acute promyelocytic leukemia (APL) is characterized by coagulopathy, leukopenic presentation and sensitivity to anthracyclines, all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). For the last 25 years, APL has been treated with a combination of ATRA and chemotherapy for induction followed by consolidation and ...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-014-0205-6
更新日期：2014-06-01 00:00:00
abstract：:Mantle cell lymphoma (MCL) is a unique lymphoma subtype comprising 6% to 8% of new lymphoma diagnoses. It is generally considered to be incurable with standard lymphoma therapies. The median overall survival (OS) is often reported to be 3 to 4 years, but more recent data suggest that the median OS may be longer than 5...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-009-0028-z
更新日期：2009-10-01 00:00:00
abstract：PURPOSE OF REVIEW:The recent development of brentuximab vedotin (BV), an antibody-drug conjugate targeting CD30-positive cells, has led to therapeutic advances in the treatment of T cell lymphomas. In this review, we discuss key studies of BV in peripheral T cell lymphoma (PTCL) and cutaneous T cell lymphoma (CTCL) and...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-020-00561-w
更新日期：2020-02-01 00:00:00
